Close

AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/20/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to AzurRx BioPharma (AZRX) Reports First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in CF Patients
(NASDAQ: AZRX) Delayed: 3.45 --0 (-0%)
Previous Close $3.45    52 Week High $5.60 
Open $10.00    52 Week Low $3.98 
Day High $3.45    P/E N/A 
Day Low $3.45    EPS $0.00 
Volume 39,332